▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / SREA

SREA — SEMPRA

—
NYSE · Utilities · Multi-Utilities · CIK 1032208 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 6,064,000,000 6,064,000,000 7,550,000,000 649,000,000 96,155,000,000 1,565,000,000 58,367,000,000
Dec 2023 7,264,000,000 7,264,000,000 8,731,000,000 732,000,000 87,181,000,000 236,000,000 53,527,000,000
Dec 2022 7,907,000,000 7,907,000,000 9,610,000,000 485,000,000 78,574,000,000 370,000,000 49,318,000,000
Dec 2021 6,479,000,000 6,479,000,000 9,836,000,000 -648,000,000 72,045,000,000 559,000,000 44,626,000,000

Annual Trend (SEC EDGAR, last 6y)

Revenues vs Net Income (last 6y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 36,331,000,000 42,455,000,000 3,075,000,000 96,155,000,000 58,367,000,000 — —
Dec 2023 30,666,000,000 36,121,000,000 2,139,000,000 87,181,000,000 53,527,000,000 — —
Dec 2022 27,580,000,000 35,107,000,000 1,318,000,000 78,574,000,000 49,318,000,000 — —
Dec 2021 24,085,000,000 30,987,000,000 3,764,000,000 72,045,000,000 44,626,000,000 — —
Dec 2019 23,039,000,000 29,077,000,000 2,055,000,000 65,665,000,000 43,860,000,000 — —
Dec 2018 5,072,000,000 — 358,000,000 60,638,000,000 41,390,000,000 — —

TTM Snapshot

Revenues TTM
$27,714,000,000
NetIncome TTM
$1,218,000,000
OpCashFlow TTM
$0
Assets (Latest)
$96,155,000,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
DUK Duke Energy CORP $96.46B $123.73 —
SRE SEMPRA $59.00B $90.25 —
XEL XCEL ENERGY INC $48.36B $77.46 —
EXC EXELON CORP $46.62B $45.56 —
PEG PUBLIC SERVICE ENTERPRISE GROUP INC $39.57B $79.40 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →